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Pediatric lung transplantation is a relatively rare procedure offered to infants, 
children, and adolescents with end-stage lung disease.  Compared to adult 
lung transplantation, the pre-operative condition of the patients, indications 
for transplantation, and the conduct of the surgery itself can be quite different.  
Through this case presentation of a 2-month-old undergoing bilateral lung 
transplantation, we discuss the unique anesthetic considerations in the 
management of the pediatric patient, and review the data on the recent era of 
pediatric lung transplantation.  Other concerns relevant to the anesthesiologist 
such as the disease states leading to transplantation, the ages at which patients 
most commonly present, and causes of post-operative morbidity and mortality 
are also presented.   
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Introduction 
The first pediatric lung transplant was 
performed in 1987 at the University of Toronto in a 
15-year-old with familial pulmonary fibrosis (1). 
Since that time, over 2000 children have received 
lung transplants worldwide, with an annual number 
ranging between 99 and 137 over the past decade (2).  
While these numbers reflect the consistency in 
the need for this procedure, they also highlight its 
relative infrequency. Pediatric lung transplants have 
accounted for only 5.5% of all lung transplants since 
1988 and represent an equally small percentage of all 
pediatric solid organ transplants (3). This lag has been 
attributed to the decreased incidence of end-stage 
lung disease in the pediatric population, a paucity of 
acceptable donors, and the modest late survival 
associated with transplantation. Nonetheless, pediatric 
lung transplantation has become a life-saving option 
for those with irreversible and progressive pulmonary 
parenchymal or vascular disease. For the 
anesthesiologist charged with managing these rare 
patients, an understanding of the indications that lead 
to transplantation, their pathophysiology, and the 
physiology of the transplanted lungs are critical.  
To provide a context for the anesthetic 
management of the child undergoing lung 
transplantation, we discuss the case of a 2-month-old 
who underwent bilateral lung transplantation for 
intractable respiratory failure. Both the unique aspects 
of this case and pediatric lung transplantation, in 
general, are presented.  
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Case Report 
A full-term infant who was the product of an 
uncomplicated gestation and an uneventful delivery 
presented to our institution at 10 weeks of age for 
bilateral lung transplant evaluation due to a 
pulmonary growth abnormality. Imaging on arrival 
demonstrated hyper-expansion of the right middle 
lobe causing both mediastinal shift to the left as well 
as compression of the right upper and lower lobes 
(Figure 1). This anatomy was reflected clinically with 
impaired ventilation and intermittent hypotension, 
presumably due to diminished venous return caused 
by the compressive effect of the right middle lobe on 
the right atrium.  
Blood gases revealed a compensated 
respiratory acidosis with PaCO2 levels chronically 
between 80-100 mmHg despite mechanical 
ventilation with paralysis and the use of inhaled nitric 
oxide (iNO, Table 1). Oxygenation, though also 
impaired, was acceptable with an increased FiO2. 
Echocardiography revealed a patent foramen ovale, 
mild right ventricular hypertrophy, pulmonary 
hypertension, and normal biventricular function.  
Medical management entailed aggressive 
diuresis and a strategy of differential lung ventilation 
to minimize the negative effects of the 
emphysematous right middle lobe. Through this 
process, the left lung was selectively ventilated via a 
cuffed oral endotracheal tube (ETT) placed in the left 
mainstem bronchus, while the right lung was 
ventilated via the tracheostomy (Figure 2). Using two 
ventilators, one for each lung, the right lung was 
ventilated more cautiously using a decreased rate and 
decreased inspiratory and positive end-expiratory 
pressures (Table 1). More ventilation that is effective 
was thereby achieved with less mediastinal shift. 
Given the infant’s irreversible defect in lung growth, 
however, the patient was ultimately put forward for 
transplantation. Within 1 week of listing, a suitable 
organ became available.  
As the patient was maintained on differential 
lung ventilation in the intensive care unit (ICU), a 
central consideration in our pre-operative evaluation 
was the safety and feasibility of maintaining this 
arrangement for transport and in the operating room. 
Due to concerns about this approach, we opted to trial 
the effect of stopping differential ventilation in the 
ICU in favor of ventilating both lungs through the 
tracheostomy at lower ventilatory settings. No 
significant change in hemodynamics or ventilation 
resulted, and so we proceeded with this traditional 
means of ventilation (Table 1).  
Once in the operating room, the tracheostomy 
 
Figure 1. A Chest X Ray of the patient B CT 
demonstrating hyperexpansion of the right middle lobe, 
displacement of the mediastinum to the left, and 
compression of adjacent lung fields. 
 
Figure 2. Differential lung ventilation.  The left lung is 
ventilated via an oral ETT placed into the left mainstem 
bronchus while the right lung is ventilated via the 
tracheostomy. 
 
Figure 3. Chest x-ray on postoperative day 1. 
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tube was exchanged for a nasal cuffed endotracheal 
tube (ETT) to allow a more exposed surgical field. A 
femoral arterial line was placed and central venous 
access was obtained. Bilateral cerebral near-infrared 
spectroscopy monitors (Somanetics INVOS, Troy, 
Michigan) were also placed to assess cerebral 
oxygenation. Anesthesia was maintained with 
isoflurane, fentanyl, and midazolam, and induction 
immunosuppressive therapy was administered as 
directed by the transplant service.  
When the donor lungs were visualized and 
deemed acceptable, the recipient dissection was 
begun via a bilateral thoracosternotomy or 
―clamshell‖ incision. Due to the patient’s size, 
tenuous respiratory status, and abnormal lung 
anatomy, the removal of the patient’s lungs and 
placement of the donor lungs was performed on 
cardiopulmonary bypass. The transplantation was 
uneventful: three anastomoses were created in a 
posterior to anterior fashion with first the bronchi on 
each side, then the pulmonary veins, and finally the 
pulmonary arteries. 
Prior to weaning from bypass, bronchoscopy 
was performed to evaluate the bronchial anastomoses 
and clear the airway of blood and secretions. 
Vasoactive agents to assist right ventricular function 
and minimize pulmonary vascular resistance were 
also initiated and included epinephrine 0.02 
Table 1: Ventilatory Settings and Blood Gases at Different Times in Management. 
 












1 Tracheostomy PCVc 38 40 5 0.7 20 7.23/121/146 
2 Right lung: Tracheostomy  
 
Left lung: 































3 Cuffed nasal ETT PCV 30-
33 
28 6 1.0 5 7.44/76/332 
4 Cuffed nasal ETT PCV 23 24 5 0.45 20 7.39/46/83 
 
1: Arrival to our institution  
2: Morning of transplantation  
3: Initial operating room (OR) ventilatory settings  
4: Following transplantation and liberation from cardiopulmonary bypass 
 
a: Peak inspiratory pressure 
b: Positive end-expiratory pressure 
c: Pressure control ventilation 
d: Synchronized intermittent mandatory ventilation/pressure control 
e: Venous blood gas 
Table 2: General goals for ventilation following transplantation (Texas Children’s Protocol). 
 
Recruitment maneuvers < 30 cm H2O 
Ventilatory Mode Pressure Control Ventilation 
Peak inspiratory pressure (PIP) < 25 cm H2O 
Positive end expiratory pressure (PEEP) 5 
Tidal volumes Donor-appropriate, < 10 cc/kg 
FiO2  0.4-0.5, goal SpO2 > 90% 
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mcg/kg/min, milrinone 0.375 mcg/kg/min, 
prostaglandin E1 0.025 mcg/kg/min, and inhaled nitric 
oxide (iNO) at 20 parts per million (PPM). Minimal 
peak inspiratory pressure, positive-end expiratory 
pressure, and inspired oxygen concentration were 
chosen to avoid further injury to the newly 
transplanted lungs (Tables 1 and 2). To augment 
ventilation, gentle recruitment maneuvers and 
suctioning were needed at regular intervals to combat 
atelectasis and prevent obstruction from bloody 
secretions. 
The patient was successfully weaned on this 
regimen. Donor lung ischemic time was 6 hours and 
47 minutes with a total CPB time of 6 hours and 5 
minutes. The anticipated post-bypass coagulopathy 
was treated with platelets, cryoprecipitate, and 
recombinant activated factor VII. A total of 3 units of 
packed red blood cells, 3 units of fresh frozen plasma, 
2 units of cryoprecipitate, and 1 unit of apheresis 
platelets were used during the bypass and post-bypass 
periods.  
On arrival to the ICU, the patient’s ABG was 
pH 7.46, paCO2 43, and paO2 275. Chest x-ray 
demonstrated areas of atelectasis and pulmonary 
congestion, but symmetric lung fields and a normally 
positioned heart (Figure 3). In the days following 
transplantation, evidence of mild graft dysfunction 
appeared with a subsequent need for increased PIP 
and a slow wean of FiO2. The allograft function 
remained acceptable, however, and progress was 
made in decreasing PIP and FiO2 over time. 
Discussion 
What are the most common indications for 
pediatric lung transplantation? 
The most common indications for pediatric 
lung transplantation include cystic fibrosis, 
pulmonary hypertension, interstitial lung disease, and 
obliterative bronchiolitis (2, 3). Of note, the 
indications largely correlate with age (Table 3). For 
those greater than 6 years, cystic fibrosis (CF) was the 
most common indication between 2000 and 2015 (2). 
In those who were less than 5 years, pulmonary 
hypertension, interstitial lung disease, congenital 
heart disease, and surfactant protein B deficiency led 
the indications for transplantation (2).  
Contraindications to pediatric lung 
transplantation likely vary among institutions, but 
absolute contraindications may include systemic 
disease with major extra-pulmonary manifestations, 
severe multi-organ dysfunction, left ventricular 
failure, and severe scoliosis.  
What are the characteristics of transplant 
recipients? 
Transplant recipients between 1988 and 2008 
had a mean age of 12±5.6 years and a mean weight of 
33.6±16.3 kg (3). Adolescents (age≥13) were the 
group most commonly transplanted (58%), followed 
by those between 2 to 12 years (31%), with infants 
(11%) being the group least commonly transplanted 
(3). On average, 3-5 infants are transplanted annually. 
When listed, infants tend to be in the ICU and either 
mechanically ventilated or on extracorporeal 
membrane oxygenation (ECMO). Some, like our 
patient, may even have a tracheostomy pre-transplant 
(Table 4). This is in contrast to older children, many 
of whom wait at home while listed and are able to 
oxygenate and ventilate without support.  
Median overall waiting times once listed are 5 
months with a range of 0-96 months; infants have a 
significantly shorter waiting time of 1 month, with a 
range of 0-7 months, perhaps reflecting the small 
number of infants who are listed as well as the 
severity of their disease state at the time of listing. 
Pre-operative evaluation 
Pre-operative assessment should focus on the 
patient’s indication for transplantation, the disease 
process’s current effect on oxygenation and 
ventilation, and any other end-organ dysfunction that 
may be present. Of particular concern, regarding co-
morbidities are those patients with cystic fibrosis. 
Given that the mutated gene, the cystic fibrosis 
transmembrane regulator (CFTR), is expressed in 
multiple organs, such patients can also present with 
diverse manifestations including diabetes, pancreatic 
exocrine insufficiency, and hepatic dysfunction 
(Table 5). Moreover, patients with end-stage cystic 
fibrosis often have multi-drug resistant bacteria. If not 
otherwise stated in the patient’s transplant plan, such 
a history should prompt a discussion regarding the 
intraoperative antibiotics to be administered during 
the transplant.  
In reviewing previous surgeries, particular 
attention should be given to prior thoracic procedures. 
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Their presence may suggest an increased risk of 
bleeding and/or a lengthy dissection period during the 
transplant due to adherent tissues.  
Vascular access 
It is our institution’s preference to use femoral 
arterial access for lung transplants. This choice has its 
basis in the clinical observation that radial arterial 
lines often seem to fail in this population. This may, 
in part, be due to the clamshell incision that can lead 
to compression of the subclavian artery, or as is the 
case in patients with cystic fibrosis, the decrease in 
systemic vascular resistance that can occur due to 
dissection-induced bacteremia. 
Central venous access is routinely obtained 
unless a patient has an indwelling peripherally-
inserted central catheter. Given the potential for 
intraoperative bleeding, adequate peripheral access 
should also be obtained.  
Not surprisingly, vascular access may be 
challenging, particularly in those who have required 
care in the ICU prior to their transplant. A thorough 
review of prior invasive lines and any history of 
major vessel occlusion may assist in planning which 
vessels to access.    
Analgesia: is there a role for a thoracic epidural? 
While a thoracic epidural would offer the 
potential advantages of improved analgesia, earlier 
mobilization, and earlier extubation, unique risks are 
present in the setting of lung transplantation that 
warrant discussion. Because most cases of pediatric 
lung transplantation are performed using 
cardiopulmonary bypass (CPB), and thus involve 
systemic heparinization, the possibility of an 
associated neuraxial hematoma is theoretically 





< 1 year  
(%) 
1-5 years  
(%) 
6-10 years  
(%) 
12-17 years (%) 
Cystic fibrosis - 4% 50% 67.8% 
Idiopathic pulmonary 
hypertension 
12.3% 27.3% 10.2% 7.7% 
Non-idiopathic pulmonary 
hypertension 
24.6% 18.2% 3.7% 1.6% 
Interstitial lung disease 19.3% 18.2% 12.9% 6.7% 
Surfactant protein B 
deficiency 
21.1% 4% 0.5% - 
ABCA3 transporter mutation 7% 4% 0.5% 0.1% 
Bronchopulmonary dysplasia 7% 3% 1.4% 0.3% 
Obliterative bronchiolitis 
(non-retransplant) 
- 8.1% 12.5% 4.6% 
Retransplant - 7% 4.6% 6.7% 
 
Adapted from the Registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Lung and Heart-
Lung Transplantation Report 








< 1 year 5/7 1/7 6/7 1/7 
1-5 years 5/16 2/16 7/16 9/16 
6-11 years 3/21 1/21 4/21 17/21 
12-17 years 3/59 2/59 5/59 54/59 
Total 16/103 (16%) 6/103 (6%) 22/103 (21%) 81/103 (79%) 
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increased. Moreover, delaying the surgery in the 
event of a bloody insertion would be detrimental to 
the donor lungs by prolonging their ischemic time
6
.  
The age of the patient at the time of 
transplantation and the presence of other co-
morbidities may also influence the decision on 
whether or not to place an epidural. On average, 
infants require 24±19 days of postoperative 
mechanical ventilation because of their accompanying 
medical issues
4
, which would make epidural 
placement less advantageous; older patients with 
cystic fibrosis, on the other hand, are commonly 
weaned from mechanical ventilation within 1-3 days  
(5). 
Consideration, then, needs to be given to the 
risks and benefits of an epidural as well as to the 
timing of placement should it be part of institutional 
practice. At our institution, we do not enough place 
epidurals due to the potential risk of a bloody tap and 
the observation that times to extubation and 
respiratory function do not appear compromised when 
using intravenous analgesics alone.  
The role and impact of cardiopulmonary bypass in 
pediatric transplantation 
In contrast to adult lung transplantation, the use 
of CPB in pediatric lung transplantation is 
commonplace. Often times the patient’s airway size 
makes one-lung-ventilation with sequential single 
lung transplantation impractical; other times the 
patient’s clinical status mandates the use of CPB to 
ensure a hemodynamically stable dissection and 
implantation. Disadvantages to CPB include an 
increased risk of coagulopathy and need for 
transfusion, and activation of the systemic 





Our patient required both CPB 
and a brief period of aortic cross-clamping for closure 
of the patent foramen ovale (PFO).  
Hemodynamics and fluid management 
Assisting right ventricular function is a key 
Table 5: Potential End-Organ Manifestations of Cystic Fibrosis. 
 
Upper airway  Chronic sinusitis 
 Nasal polyps 
Pulmonary  Productive cough 
 Wheezing and/or bronchospasm 
 Hemoptysis 
 Pneumothorax 
 Pulmonary hypertension 
Cardiovascular  Right ventricular dysfunction (cor pulmonale) 
Gastrointestinal   Gastroesophageal reflux 
 Meconium ileus in the neonate 
 Distal intestinal obstruction in adults 
 Intussusception 
 Fibrosing colonopathy 
Hepatobiliary  Gallstones 
 Cirrhotic liver disease 
 Hepatic steatosis 
Exocrine pancreas  Malnutrition 
 Steatorrhea 
 Fat-soluble vitamin deficiency 
Endocrine pancreas  CF-related diabetes mellitus 
Bone and joints  Fractures 
 Arthritis 
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goal in patients undergoing lung transplantation, 
especially in the pre-bypass period when lung 
function is marginal. While it would ideal to 
minimize pulmonary vascular resistance through 
manipulating oxygenation, ventilation, and pH, this 
can be challenging due to the intrinsic lung 
abnormality. As such, one should have inotropes and 
pressors available to assist contractility as needed and 
to maintain an adequate coronary perfusion pressure 
to avoid right ventricular ischemia. Post-bypass, right 
ventricular function may be hyperdynamic assuming 
adequate graft function due to normalization in right 
ventricular afterload compared to the pre-transplant 
state. Vasoactive agents that can assist right 
ventricular function post-transplant include 
epinephrine, milrinone, prostaglandin E1, and iNO.  
Because transplanted lungs lack an intact 
lymphatic system, caution must be used with the 
administration of blood products and crystalloid in the 
immediate post-transplant period to avoid pulmonary 
congestion and subsequently impaired oxygenation 
and ventilation (6). This goal is often at direct odds, 
however, with the need to achieve hemostasis. As 
evidenced in the patient described, bypass times can 
often be several hours, leading to deficiencies in 
platelets, fibrinogen, and clotting factors that require 
replacement. Given that the transfusion of blood 
products is, at times, inevitable, one should look 
carefully for any change in ventilatory compliance 
and oxygenation that may indicate the onset of 
pulmonary edema. Such a change may prompt a new 
strategy towards the use of recombinant factor 7a or 
Table 6: Physiologic changes affecting lung function following transplantation. 
 
Anticipated changes influencing lung function End-results of these changes 
 
 
Vagal denervation and loss of afferent stimuli  
 Resting bronchodilation 
 Less effective cough 
 Decreased clearance of secretions 
 Decreased response to hypercapnea 
 Poor coordination between thoracic and 
abdominal musculature 
 
Absence of lymphatic drainage  
 Decreased lung compliance 
 Potential for worsening pulmonary edema 
with volume administration 
 
 
Table 7: Common Causes of Death in Pediatric Lung Transplant Recipients by Age at Transplantation, 1990-2015. 
 
 
Cause of death 
0-30 days 
(n = 151) 
No. (%) 
31 days – 1 year 
(n = 212) 
No. (%) 
>1-3 years 
(n = 266) 
No. (%) 
>3-5 years 
(n = 128) 
No. (%) 
>5 years 




0 24  (11.3) 96  (36.1) 49 (38.3) 65 (46.4) 
Infection 23  (15.2) 72  (33.9) 43  (16.2) 22 (17.2) 10 (7.1) 
Graft Failure 44  (29.1) 41  (19.3) 70  (26.3) 29 (22.7) 31 (22.1) 
Acute rejection 3     (2)  5    (2.4)  6    (2.3)  3   (2.3)  1   (0.7) 
Malignancy 0 12  (6.6)  8    (3.0)  4   (3.1) 12 (8.6) 
Multiple Organ 
Failure 
16  (10.6) 25 (11.8) 14   (5.3)  5   (3.9)  9   (6.4) 
Cardiovascular 22  (14.6)  9   (4.2) 4     (1.5)  1   (0.8)  1 (0.7) 
Technical 22  (14.6)  5   (2.4) 6     (2.3)  3   (2.3)  2 (1.4) 
 
Adapted from the Registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Lung and Heart-
Lung Transplantation Report 
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another low-volume pro-coagulant like the 
prothrombin complex concentrates should 
coagulopathy remain an issue.  
Ventilating and oxygenating the newly 
transplanted lungs 
To avoid further injury to the donor lungs, our 
ventilatory strategy seeks to minimize the peak 
inspiratory pressures, positive-end expiratory 
pressures, and FiO2 necessary to achieve adequate 
ventilation and oxygenation (Table 2). Common 
etiologies that may cause an acute increase in airway 
pressures include obstruction of the airways or ETT 
with blood or secretions, or airway compression due 
to surgical manipulation. Frequent suctioning either 
by suction catheter or with a bronchoscope is often 
necessary. When deciding what tidal volume is most 
appropriate with which to ventilate, one should 
consider the size of the donor patient (as this 
individual may have been smaller or larger than the 
recipient), and whether any lobes of the donor lung 
were surgically resected (as may be the case in 
significant size-mismatch).  
Physiology of the newly transplanted lungs 
Transplantation interrupts not only the donor 
lung’s lymphatic drainage, but also its vagal 
innervation (Table 6). Vagal denervation manifests as 
resting bronchodilation, decreased ventilatory 
response to hypercapnea, diminished cough, and 
reduced mucociliary clearance. Proximal to the 
anastomosis, however, airway reflexes and 
mucociliary clearance are retained. Thus, if the upper 
airway or trachea is to be instrumented as in 
bronchoscopy, care should be taken to topicalize the 
airway with local anesthetic as one would in any other 
patient. Of note, hypoxic pulmonary vasoconstriction 
and the response to inhaled beta-agonists are 
preserved in the donor lung.  
What are the concerns in the post-operative period 
following lung transplantation? 
Post-transplant complications can be 
categorized into 3 phases: the immediate phase, 
representing the first week after transplantation; the 
early phase, including the first 3 months; and the late 
phase, entailing the time beyond 3 months.  
Immediate and early phase complications 
Primary graft dysfunction and ischemia-reperfusion 
Injury 
These represent the most common graft 
complications following transplantation, occurring in 
20-30% (9), and are the leading causes of death 
within the first 30 days posttransplant (2). The two 
conditions are inter-related in that primary graft 
dysfunction is the product of multiple insults of which 
ischemia-reperfusion injury is a major contributor (8). 
The clinical spectrum can range from mild hypoxemia 
with few infiltrates on chest x-ray to severe 
respiratory distress syndrome (8, 9).  
Rejection 
Hyperacute rejection is rare as it represents a 
previous exposure to foreign tissue antigens that are 
generally screened for. Acute rejection, however, is 
more common and occurs at a rate comparable to that 
in adults. The majority of episodes of acute rejection 
occur in the first 6 months after transplant (10). 
Infants appear to have a much lower incidence 
compared to other pediatric age groups, perhaps 
because of their relatively immature immune systems 
(11).  
Infection 
Infection, always a concern following any 
transplantation, is of greater risk in the lung transplant 
recipient. Not only is there direct contact of the graft 
with the external environment, but there is also donor 
colonization of the airways and a diminished ability to 
cough due to vagal denervation and potential phrenic 
nerve injury. Of all age groups, infants are 
particularly susceptible to severe and fatal viral 
infections.  
Surgical complications 
Anastomotic complications, although rare, can 
involve bronchial dehiscence or pulmonary vascular 
stenosis. Bronchial stenosis occurs in approximately 
10%, and can be treated effectively with serial 
dilation or angioplasty (10). Issues with the vascular 
anastomoses can be studied with perfusion lung scans 
or cardiac catheterization, often performed within the 
first 24 hours of transplant as a screening tool.  
Late phase complications 
Issues plaguing the late phases following 
transplantation include bronchiolitis obliterans (OB), 
malignancy, and immunosuppressant-related side 
effects.  
Bronchiolitis obliterans 
OB is a histiologic diagnosis with a clinical 
surrogate of decreased forced expiratory volume in 1 
second (FEV1). It is a major cause of death and the 
Trivedi et al.                                              Anesthesia for pediatric lung transplantation: Case presentation and Review of … 
 Journal of Cellular & Molecular Anesthesia (JCMA) 
132 
need for retransplantation in those who survive 1 year 
following transplantation, and occurs in nearly 50% 
of long-term survivors (12).  
Malignancy 
The overall incidence of malignancy is 5-10%, 
and is mainly attributable to post-transplant 
lymphoproliferative disease (PTLD) (10). Primary 
Epstein-Barr virus (EBV) is a risk factor for PTLD 
(13). Children may be more susceptible to this 
complication because they are often seronegative for 
EBV at the time of transplantation, and can thus 
acquire a primary EBV infection thereafter.  
Immunosuppresant-related side effects 
Some of the most common causes of morbidity 
following pediatric lung transplantation are related to 
immunosuppressive therapy. Most patients are on a 
regimen of triple immunosuppression entailing an 
antimetabolite (azathioprine or mycophenolate 
mofetil), a calcineurin inhibitor (cyclosporine or 
tacrolimus), and systemic steroids as maintenance (8). 
Side effects that are particularly relevant to the 
anesthesiologist can include hypertension, diabetes, 
renal dysfunction, and seizures. Within 1 year, the 
prevalence of hypertension is 42%, renal dysfunction 
10%, diabetes 21%, and hyperlipidemia 5% (2). At 5 
years, the prevalence increases to 69%, 30%, 31%, 
and 18%, respectively (2).  
What is the survival following transplantation? 
Survival has increased over the years due to 
advances in surgical technique, immunosuppressive 
regimens, patient selection, and post-transplant care. 
However, as noted in a recent review of the preceding 
2 decades of pediatric lung transplantation, the 
improved survival is attributable only to an increased 
1-year survival (3). Beyond the first year, survival has 
remained unchanged, and remains low compared to 
heart and other solid organ transplantations.  
The 5-year survival of pediatric lung transplant 
recipients between January 1990 and June 2014 was 
51%, a number comparable to that observed in the 
adult population during the same period of time (2).
 
Among the different ages of pediatric patients, no 
significant difference in survival was noted in pair-
wise comparisons (3). Survival in the first year post-
transplant, however, was lowest in infants, perhaps 
reflecting the effects of infection on their naïve and 
suppressed immune systems. Beyond one year, infant 
survival was comparable to that of other age groups.  
The functional status of pediatric lung 
transplant recipients has been reported to be very 
good. 86% of those surviving 5 years after 
transplantation have no activity limitations (2).  
What are the major causes of death? 
The leading causes of death following pediatric 
lung transplantation include graft failure, infection, 
and bronchiolitis obliterans (2)
 
(Table 7). In the first 
year after transplantation, infection and graft failure 
account for the majority of deaths, whereas 
bronchiolitis obliterans is the major cause after the 
first year. Malignancy and multi-organ system failure 
are also significant contributors.  
Risk factors for increased early and overall 
mortality include preoperative chronic steroid use, 
pre-transplant ventilatory dependence, and re-
transplantation.  
An update on our patient  
Our patient's postoperative recovery was 
initially hindered by infectious pulmonary 
complications, including a CMV pneumonitis and 
bacterial pneumonia. She was able to overcome these 
issues, though, and was weaned off the ventilator. Her 
tracheostomy was decannulated shortly thereafter and 
she was subsequently discharged home, 
approximately 3 months after transplantation. 
Conclusion 
Pediatric lung transplantation has become an 
accepted therapy for selected patients with otherwise 
untreatable pulmonary parenchymal or vascular 
disease, and represents a growing field in medicine. 
Unique challenges include the limited availability of 
suitable donor organs, the prevalence of bronchiolitis 
obliterans, infection, and graft failure following 
transplantation, and the related effort to maximize 
survival, growth, and quality of life in these patients. 
 Anesthesiologists can contribute greatly to 
the care of these patients in their intraoperative 
management during the transplantation itself or in the 
post-transplant period when the patient returns for 
biopsies, bronchoscopies, or procedures otherwise 
common to the pediatric population. Care during the 
transplantation should focus on careful ventilation, 
oxygenation, and fluid management to optimize graft 
function. Post-transplant anesthetics, beyond an 
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assessment of graft function, should direct attention to 
the immunosuppressant-induced and primary disease- 
related comorbidities present. 
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